Tectonic Therapeutic (TECX) Competitors

Evotec (NASDAQ:EVO) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Does the media prefer EVO or TECX?

In the previous week, Tectonic Therapeutic had 3 more articles in the media than Evotec. MarketBeat recorded 4 mentions for Tectonic Therapeutic and 1 mentions for Evotec. Evotec's average media sentiment score of 1.11 beat Tectonic Therapeutic's score of 0.54 indicating that Evotec is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, EVO or TECX?

Evotec has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.17, meaning that its share price is 217% more volatile than the S&P 500.

Do analysts rate EVO or TECX?

Evotec currently has a consensus price target of $5.93, suggesting a potential upside of 42.97%. Tectonic Therapeutic has a consensus price target of $83.60, suggesting a potential upside of 287.94%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Tectonic Therapeutic	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.33

Is EVO or TECX more profitable?

Tectonic Therapeutic has a net margin of 0.00% compared to Evotec's net margin of -26.34%. Evotec's return on equity of -21.51% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.34%	-21.51%	-10.54%
Tectonic Therapeutic	N/A	-30.13%	-27.52%

Which has stronger valuation and earnings, EVO or TECX?

Tectonic Therapeutic has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$862.40M	1.71	-$212.18M	N/A	N/A
Tectonic Therapeutic	N/A	N/A	-$57.98M	-$7.31	-2.95

Do insiders and institutionals have more ownership in EVO or TECX?

5.8% of Evotec shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Tectonic Therapeutic beats Evotec on 10 of the 14 factors compared between the two stocks.